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The temporal and spatial development of Parkinson’s disease has been characterised as the progressive formation of α-synuclein 
aggregations through susceptible neuronal pathways. This article describes a new model for this progression mechanism in which 
Parkinsonian damage moves over time through the nervous system by the combined effect of the reaction kinetics of pathogenesis and 
molecular diffusion. In the reaction-diffusion model, the change from a healthy state to the disease state advances through the nervous 
system as a wave front of Parkinsonian damage, marking its path by accumulations of damaged α-synuclein and neurotoxic levels of 
oxidative species. Progression according to this model follows the most vulnerable routes through the nervous system as described by 
Braak’s staging theory and predicts that damage will advance at differing speeds depending upon the level and number of risk factors, 
in a manner that gives new insights into the variations with which Parkinson’s disease develops. 
 
 
I. INTRODUCTION 
The pathology of Parkinson’s disease is characterised by the 
progressive appearance in the nervous system of aggregations 
(consisting principally of damaged α-synuclein) that follow ‘an 
ascending course with little inter-individual variations’ 
[Braak, 2003a]. The same authors have suggested that this 
spatially progressive sequence could be achieved [Braak, 
2003b] by an invading pathogen which enters the enteric 
nervous system (ENS) and proceeds by backward projection to 
the brain stem and hence the brain itself. The Braak 
progression theory concerns the long term development of 
Parkinson’s disease, and is therefore highly important in 
building an overall understanding of Parkinson’s from 
beginning to end.  
The idea that an invading pathogen can itself propagate 
through the nervous systems has been thrown into question by 
the finding [Pan-Montojo, 2010] that Parkinsonian damage an 
animal model caused by intragastrically administered toxin is 
not accompanied by traces of the toxin. This paper describes an 
explanation of progression that overcomes this problem. 
Specifically, we propose that, while an invading pathogen may 
initiate Parkinsonian damage locally, it is the endogenous 
pathogenesis mechanism of the disease, rather than the 
pathogen, that causes subsequent transmission and progression.  
In particular, we describe a model for the spread of 
Parkinsonian damage by a combination of (i) the reaction 
kinetics of pathogenesis which cause the local growth of α-
synuclein misfolds (αSYNmis) and the rise of reactive 
oxidative species (ROS) to neuro-toxic levels, plus (ii) 
molecular diffusion of these pathogenic products.  We 
envisage the process as operating as follows: an initial trigger 
mechanism (e.g. an external pathogen or other stress factor) 
overthrows the homeostatic neurochemical balance within a 
localised compartment somewhere in the nervous system. This 
causes local pathogenesis whereby levels of α-synuclein 
increase and reactive oxidative species (ROS) rise to 
neurotoxic levels that create the disease state.  
In this model it is the neurochemical reaction dynamics of 
pathogenesis, combined with molecular diffusion, which 
communicates the elevated ROS and protein damage to 
neighbouring compartments. This causes the effected 
compartments themselves undergo pathogenesis, such that 
Parkinsonian damage spreads sequentially from compartment 
to compartment. The rate of progression of the disease state 
depends upon the kinetics of the pathogenic reaction and this, 
in turn, is determined by the severity of the risk factors and the 
vulnerability of individual neurons.  
II. A MODEL FOR THE PATHOGENESIS OF PARKINSON’S 
DISEASE 
A. Pathogenesis as a critical transition within a neuronal 
compartment. 
Despite being a well-known phenomenon in biology 
[Murray, 2002, Volpert, 2009], the spread of chemical species 
and concentrations by reaction-diffusion (R-D) has not 
previously been considered as a progression mechanism for 
Parkinson’s disease. This is probably because the 
neurochemical kinetics of Parkinson’s pathogenesis has not 
previously been understood (see, for example, [Lotharius, 
2002, Hattori, N, 2004, Shin, 2009, Schapira, 2011]). 
However, a recently developed mathematical model [Cloutier, 
2012a] of α-synuclein and oxidative metabolism simulates the 
pathogenesis of Parkinson’s within a neuronal compartment, 
and gives an analytical picture of the pathogenic process 
[Cloutier, 2012b]. Specifically, when placed under sufficient 
stress from Parkinsonian risk factors, the model exhibits a 
sudden (and apparently spontaneous) transition from healthy 
neurochemical conditions to a disease state that creates 
Parkinsonian damage within the neuronal compartment. The 
abrupt transition from healthy to a disease state occurs when 
risk factors acting on the neuronal compartment exceed a 
critical level. Beyond this critical level, a bifurcation occurs 
that cause the concentrations of misfolded α-synuclein 
  
 
(αSYNmis) and reactive oxygen species (ROS) to undergo 
what is known in natural sciences as a critical transition 
[Scheffer, 2009], as they increase to high levels. In most cases, 
but not necessarily, the switch to neuro toxic levels is 
permanent, persisting even after the stress initiating it has been 
removed [Cloutier, 2012b]. (See Supplementary Materials 
SM2 for a simplified model of the pathogenic mechanism). 
This model of Parkinson’s pathogenesis arose from 
mathematical modelling of brain energy metabolism [Cloutier, 
2012c], and how it interacts with the neurochemical dynamics 
of reactive species and α-synuclein metabolism. However, 
although it is a mathematical modelling exercise, the models 
were calibrated using measured changes in neurochemicals 
[Lowry, 2004], and the pathogenesis finding has been 
investigated in animal models. Specifically, Paraquat was 
administered periodically to freely moving rats in a manner 
used in simulations, and continuous long term measurement of 
cerebral nitric oxide (NO) reproduced the predicted transition 
to a Parkinsonian state [Finnerty 2013]. 
B. External stress as an initiator of the critical transition to 
Parkinson’s disease. 
To illustrate how an external pathogen might initiate 
Parkinson’s disease, we start with the example used by Braak 
[Braak, 2003b], but in a much simplified form. Specifically, 
we consider that the start point is in the ENS and this is 
connected to the brain stem by a single neuronal pathway in 
which all parts of the neuronal tissue have uniform properties. 
Figure 1 illustrates this situation where the invading pathogen 
is shown as an external toxic stress and the approximate 
distance from ENS to the brain stem is 1 metre.  
 
Figure 1: A hypothetical continuous neuronal pathway from ENS to brain stem 
 
Figure 2 shows what happens in the model of pathogenesis 
when an invading pathogen (in this case a transient loading of 
external toxin) enters the compartment of the simulated neuron 
at its closest point to the pathogens point of entry. Figure 2 
shows the permanent change in the steady state level of 
reactive oxygen species and α-synuclein misfolds that is 
caused by the toxic stress. Below a critical level of external 
stress (duration and magnitude), the compartment is not 
switched permanently and levels of ROS and αSYNmis 
recover to their previous levels (see simulations in [Cloutier, 
2012a, b] for details). This is compatible with practical 
observations on the impact of low or infrequent exposures to 
certain chemical used in agricultural and industrial 
applications. 
The external stress in Figure 2 exceeds the critical point that 
causes a bifurcation [Kuznetsov, 2004] to occur in the 
nonlinear kinetics of the ROS/ αSYNmis interaction, resulting in 
the steady state levels of ROS and αSYNmis to permanently 
increase to levels where the development of Parkinson’s 
disease is initiated by α-synuclein accumulation and neurotoxic 
oxidative damage. The external toxic stress used in this 
simulation is transient, lasting only 40 days (from day 10 to 
day 50). A transient external stress is simulated to emphasize 
the point that, despite the removal of the initiating stress, the 
change to a Parkinsonian state in the neuronal compartment 
remains. That is to say, the external stress/invading pathogen 
effectively operates a one-way switch from healthy 
homeostasis to a stable disease state in the neuronal 
compartment. 
 
Figure 2: Concentrations of ROS and αSYNmis in compartment 1 switch from 
low healthy levels to high levels triggered by exposure to external toxic stress 
from day 10 to day 50.  
 
C. Transmission of the disease state to adjacent neuronal 
compartments 
Figure 3 illustrates the onward transmission of high levels of 
ROS and αSYNmis in terms of how the pathogenic switch to 
high levels of ROS and αSYNmis in compartment 1, then 
causes a similar transition to be triggered in the immediately 
adjacent area (compartment 2). Parkinsonian damages thus 
progresses from the first to the second compartment without 
the initiating pathogen. This process is illustrated in Figure 3 
where the disease state from the compartment 1 (ROS 1/ 
αSYNmis 1), triggers a switch in compartment 2 to a 
Parkinsonian state with elevated concentrations (ROS 2/ 
αSYNmis 2).   
Figure 3 illustrates the point that the initial trigger 
mechanism for Parkinson’s need only be the initial agent for 
pathogenic change and does not progress further. The 
separation between the initiating agent at the disease start point 
and the subsequent spread by endogenous pathogenic 
transition rationalises the results [Pan-Montojo, 2010]. 
 
  
 
 
Figure 3: The raised levels of concentrations of ROS and αSYNmis in 
compartment 1 trigger a corresponding switch in ROS and αSYNmis in 
compartment 2.  
 
III. A REACTION-DIFFUSION MODEL OF PARKINSON’S 
PROGRESSION  
The explanation in the previous paragraphs can be extended 
to model a continuous pathway through the nervous system as 
a set of contiguous neuronal compartments in which the 
pathogenic transition is communicated from one compartment 
to the next, like a line of falling dominos. However, this 
‘passing on’ of the disease state from one compartment to 
another is more elegantly (and correctly) represented 
mathematical by considering the continuous neural pathway to 
consist of a sequence of neuronal compartments which become 
thinner and thinner. In the limit, as the compartments become 
infinitesimally thin, the model becomes a partial differential 
equation [Murray, 2002] that combines molecular diffusion of 
ROS and αSYNmis with the reaction equations for 
pathogenesis (see Supplementary Material SM2 for details of 
the reaction-diffusion equations for Parkinson’s progression).   
A. Simulating reaction-diffusion progression from the ENS 
to the brain stem. 
To illustrate how reaction-diffusion would work as a 
progression mechanism, we simulate the progression of 
Parkinsonian damage described in [Braak, 2003b] from the 
ENS to the brain stem by computing the Parkinsons’s reaction-
diffusion equation along the hypothetical 1 metre neuron of 
Figure 1. Since the intention is to the principle of how 
Parkinson’s can progress by reaction-diffusion, we assume that 
the neuron has uniform properties along its entire length.  
The computation begins with initial conditions in which 
ROS and αSYN concentrations are at levels compatible with a 
healthy neuronal state along the full one metre length of the 
hypothetical neuron (Figure 1).  An initial external toxic stress 
is applied to the start point (the synaptic arbour in Figure 1) 
and the partial differential equations which govern variations 
in concentrations of ROS and αSYNmis are calculated (See 
SM2) at each point along the length over a 20 year time period.  
Consider first a neuron with no external risks from excessive 
aging, head trauma, genetic disorder or toxic damage (apart 
from the initial toxin exposure at the start point).  
Figure 4 shows the development in the concentrations of 
ROS and αSYNmis over time and distance from the start point 
for this situation. As can be seen, the switch to a disease state 
propagates from the start point at time zero in the form of a 
wave front. It finally reaches the end point (the soma) 
approximately 7 years after toxic stress initiated the disease 
state at the start. This propagation time is of the same order of 
magnitude as might be expected for the progression of 
Parkinsonian damage in reality.  For the purposes of 
comparison with the alternative of diffusion alone, the 
progression over the same length by diffusion of ROS and 
αSYNmis, would be much slower. Using published data for 
diffusion rates it would take approximately 300 years for 
Parkinson’s to progress the one metre from ENS to brain stem. 
(See Supplementary Material SM2). Thus reaction-diffusion 
gives a plausible progression time for Parkinson’s initial step 
from ENS to brain stem – now we consider how changes in 
known Parkinsonian risk factors might change the speed of 
progression of the disease 
 
Figure 4: Profile over time and length of a hypothetical 1 metre neuron with 
progression by reaction-diffusion 
 
IV. THE IMPACT OF RISK FACTORS ON THE PROGRESSION OF 
PARKINSON’S 
In the mathematical model that simulates pathogenesis, the 
speed and magnitude of the transition from healthy to disease 
state is strongly influenced by the size and number of 
Parkinsonian risk factors [Cloutier,  2012c, Wellstead, 2012]. 
In this section we demonstrate that this influence transfer to the 
reaction – diffusion model of progression, such that the speed 
with which Parkinson’s progresses is also a direct function of 
Parkinsonian risk factors. We begin with the influence of aging 
on progression speed.  
  
 
A. Ageing 
Ageing is the main risk factor for developing Parkinson’s 
disease, and has a strong influence on the model of the 
pathogenic mechanism for local transition to the disease state. 
It is therefore of great interest to see if this influence extends to 
rate at which of Parkinsonian damage progresses through the 
nervous system. This can be illustrated by adjusting the aging 
rate in the reaction-diffusion equations – the level of aging is 
modelled by the strength of the brain energy metabolism.  
Figure 5 (i) shows the progression of Parkinsonian damage 
for a higher aging rate than normal (weaker brain energy 
metabolism). In this case Parkinsonian damage progresses the 
one metre along the model neuron in approximately 3.5 years, 
significantly faster than in the normal aging case of Figure 4. 
The converse is also true and low age effect (stronger brain 
energy metabolism) slows progression. Figure 5(ii) illustrates 
how a reduced the aging level also reduces the speed of 
progression:  in the simulation shown Parkinsonian damage 
has not reached the soma 15 years after the initial toxic stress 
at the ENS.  
Our models do not precisely classify the aging rate. 
Nonetheless, the trends in the progression (slower for low 
aging rate – faster for high aging rate) are consistent with the 
variable nature of progression observed in practice. It also 
raises point that the ENS may receive frequent damaging toxic 
insults which, because of a strong brain energy metabolism 
never progress sufficiently fast to the brain. 
 
Figure 5 (i) : Profile over time and length of a hypothetical 1 metre neuron 
with progression by reaction-diffusion with high aging (weak brain energy 
metabolism) 
 
 
Figure 5 (ii) : Profile over time and length of a hypothetical 1 metre neuron 
with progression by reaction-diffusion with low aging (strong brain energy 
metabolism) 
 
 
B. Genetic predisposition 
Parkinson’s disease is only a truly genetic condition in a 
minority of cases. Nonetheless, mutations in certain genes 
create a predisposition to Parkinson’s disease. This is reflected 
in the model of pathogenesis (SM2) in which increased genetic 
irregularity lowers the switching threshold to the Parkinsonian 
state and increases the toxicity of the disease state, [Cloutier, 
2012c]. Thus genetic disorders are predicted to make 
Parkinson’s more likely and more severe.   
The corresponding impact of genetic disorder on the speed 
of progression is simulated in Figure 6 (i) which shows that for 
a modest level of genetic mutation, the time to progress from 
synaptic terminal to the soma is reduced from 7 years, to 
approximately 3.5 years. Figure 6 (ii) shows the corresponding 
plot for a high level of genetic irregularity (corresponding to 
familial Parkinson’s) in which the progression time over the 1 
metre length is reduced to less than one year.  
The large variability in progression times with different risk 
factors (in this case with age and genetic predisposition, but in 
practice with other risk factors as well) is in line with, and 
gives potential reasons for, the great variabilities observed in 
the severity and progression of Parkinson’s in practice.   
 
  
 
 
Figure 6 (i) : Profile over time and length of a hypothetical 1 metre neuron 
with progression by reaction-diffusion with moderate genetic predisposition 
 
 
 
Figure 6 (ii) : Profile over time and length of a hypothetical 1 metre neuron 
with progression by reaction-diffusion with strong genetic predisposition 
 
C. Sensitivity to diffusion rates: α-synuclein  
The protein α-synuclein is an unstructured protein which can 
diffuse at various rates depending on its conformation [Ducas 
2014]. Likewise, uncertainty of the role of active transport of 
α-synuclein in misfolded form, lead us to consider the 
sensitivity of progression in the R-D model to variations in 
diffusion rate. In particular, we computed the R-D model for a 
range of α-synuclein diffusion rates. The results show that the 
progression time by reaction-diffusion is indeed sensitive to 
the diffusion rate of α-synuclein. The nominal diffusion rate 
used in the R-D computations (see SM2) is Da = 72000 m
2
h
-1
  
and gave a progression time of approximately 7 years. 
Increasing the diffusion rate by a factor of four (the range 
given in [Ducas 2014]) gives a faster progression time of 
approximately 3 years. This is over twice as fast as with the 
nominal diffusion rate, but still within the time span that is 
reasonable for Parkinsonian progression. 
D. Sensitivity to diffusion rates: reactive oxygen species 
For the model of pathogenesis, all oxidative products of 
Parkinsonian malfunction were amalgamated into one general 
ROS. To represent the diffusion of ROS we used the value 
measures for oxygen ions in [Katayama, 2005] of Dros = 
309600 µm
2
 h
-1
. In fact, in our model, the diffusion coefficient 
of ROS has little impact on the progression times. The 
diffusion coefficient (Dros) can be increased or decreased by 
two orders of magnitude, without any significant difference to 
the calculated progression times. The prediction is therefore 
that the progression speed of Parkinson’s is largely 
independent of the diffusion rate of ROS.  
V. DISCUSSION  
In this article we have focussed on an example where 
Parkinsonian damage is initiated in the ENS. This was done for 
two reasons. First in order to explain how the R-D model of 
the progression mechanism offers a rational explanation of 
how invading pathogens can start Parkinson’s without 
continuing with the process – thus resolving the ‘Pan-Montojo 
paradox’. And second to show how the R-D model explains 
the differing progression rates of Parkinson’s disease and its 
dependence upon the level of risk factors and intrinsic 
vulnerability. 
Other start points for Parkinson’s disease 
The R-D progression model is of course equally applicable 
for Parkinson’s disease initiated at other start points. For 
example, external start points such as the olfactory bulb, 
[Braak 2008] and areas of the nervous systems which are 
subject to unsupportable energetic loading [Wellstead, 2010, 
Bolam, 2012] such as the SN [Matsuda 2009, 2012]. 
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Supplementary Material. 
 
SM1. The Parkinson’s feedback motif – a simplified mathematical model of oxidative and protein metabolism. 
The pathogenic switching of states displayed by the full mathematical model [Cloutier, 2012a] can be represented accurately in 
the simplified model – or motif [Cloutier, 2012b] – shown in Figure SMF1. The key feature of the motif is a feedback loop, in 
which the concentration of ROS and αSYNmis are regulated by the endogenous influence of ROS concentration on the production 
rate (v3) of αSYNmis  and a corresponding endogenous influence of αSYNmis concentration on the production rate (v1) of ROS. 
The influence of external risk factors is coded into the ‘input’ variables (S1, S2, S3, S4) and how they change the production and 
removal rates of ROS (v1, v2) and αSYNmis (v3, v4).  
The differential equations which describe the motif’s dynamical behaviour are given in TABLE SMT1 and the inputs are defined 
in TABLE SMT2  
      
 
Figure SMF1: Core Feedback Motif for the reaction dynamics of Parkinson’s pathogenesis 
 
TABLE SMT1 Core feedback motif model 
Symbol Name 
Steady-state 
value  
Differential equations and rates 
State variables (µM) 
 
ROS 
Reactive 
oxygen species 
1 
21  


t
ROS
 
αSYNmis 
Misfolded                
α-synuclein  
1 
43 




t
SYNmis
 
Fluxes* (µM∙h-1)  
v1 
ROS 
generation 
468 










































4
4
111
1
1
syn
syn
asyn
K
SYNmis
K
SYNmis
dSk




  
v2 ROS removal 468 222 SROSkv   
v3 
αSYNmis 
generation 
0.007 333 SROSkv   
v4 
αSYNmis 
removal 
0.007 444 SSYNmiskv    
Parameters** k1 = 468; k2 = 468; k3 = 0.007; k4 = 0.007; dαSYN  = 15; KαSYN = 8.5; 
* Signals S1-4 have the following default values: S1 = 0; S2-4 = 1.  
** Parameters units are: µM∙h-1 for k1; h
-1
 for k2, k3, k4; µM for KαSYN; dimensionless for dαSYN.  
  
  
 
TABLE SMT2 Inputs to the core motif and PD pathogenic factors 
Input Corresponding pathogenic mechanisms 
S1 
Internal and external oxidative stresses 
The following mechanisms will act to increase the input  S1 : 
I. External oxidative stress from toxins [9, 31]  
II. Mitochondrial dysfunction [15] including age related decline in efficiency [16, 17] 
and effects of calcium [5] 
III. Dopamine induced oxidative stress [5]  
IV. Elevated free iron level and impaired free radical defence [32] 
S2 
Age-related anti-oxidative mechanisms  
The following mechanisms will act to decrease the input S2 : 
I. Reduced anti-oxidative capability and GSH buffering with age [33]  
II. Decline in efficiency of energy metabolism [34, 35] 
III. Reduced effectiveness of glucose uptake and utilisation (i.e. potentially leading to 
reduced PPP flux) 
S3 
Influence of genetic damage/mutation 
The following mechanisms will act to increase the input S3 : 
I. Over expression of the αSYN gene [36] 
II. Elevated mutation rate of αSYN  [36] 
S4 
Protein clearance mechanisms 
The following mechanisms will act to decrease the input S4 : 
I. Parkin gene mutations impairing ubiquitination pathway [36, 22]  
II. Reduction in available ATP potentially impairs proteins clearance  
 
 
SM2. The reaction-diffusion equations for the progression of Parkinson’s 
The reaction-diffusion equation for the progression of ROS and αSYNmis along a hypothetical one-dimensional pathway: 
 
[
𝜕𝑅𝑂𝑆
𝜕𝑡
𝜕𝛼𝑆𝑌𝑁𝑚𝑖𝑠
𝜕𝑡
] = [
𝑣1 −𝑣2
𝑣3 −𝑣4
] + [
𝐷𝑅𝑂𝑆 0
0 𝐷𝛼𝑆𝑌𝑁𝑚𝑖𝑠
]
[
 
 
 
𝜕2𝑅𝑂𝑆
𝜕𝑥2
𝜕2𝛼𝑆𝑌𝑁𝑚𝑖𝑠
𝜕𝑥2 ]
 
 
 
 
 
Where: 
Dros is the diffusion coefficient for ROS 
DαSYNmis is the diffusion coefficient for damaged α-synuclein 
Time is denoted by the variable t, and x is the position along the pathway. The fluxes v1, v2, v3, v4 are as defined in SM1. 
 
We assumed that an external pathogen has created an initial α-synuclein misfold concentration of 17 µM at start point. This was 
used as it corresponded to the steady state level of αSYNmi in the model when in the disease state [Cloutier, 2012a]. However, the 
physiological concentration of α-synuclein varies on the location within a neuron, but is on average 100 µM [Raichur, 2006], and 
under healthy conditions approximately 1% of the protein is misfolded [Sneppen, 2009]. The concentration of α-synuclein 
misfolds in Parkinsonian brains has been calculated [Chiba-Falek, 2006] as four times greater than in healthy brains, so that on 
average the concentration of mis-folded α-synuclein in a Parkinsonian state could be expected to be approximately 4 µM. 
However, this does not account for variations throughout a neuron and other factors remarked upon by [Chiba-Falek, 2006]. 
Hence use of an initial α-synuclein misfold concentration of 17 µM is highly conservative. 
 
 
Diffusion coefficients:  
  
 
ROS 
For the reactive species, ROS we used the value of Dros = 309600 µm
2
 h
-1 
 as measured for oxygen ions in [Katayama, 2005].  
αSYNmis 
The diffusion coefficient for α-synuclein misfolds is more problematic.  Protein diffusion coefficients within a cell have been 
measured [Kuhn, 2011] as varying between 72,000 µM
2
/h (in cytoplasm) and 216,000 µM
2
/h (in cytosol).  In the calculation, we 
used the faster of these two – the cytosolic rate of 216,000 µM2/h  - as the maximum possible speed of diffusion for α-synuclein 
misfolds. In reality the diffusion rate could be slower than this because: (i) misfolded α-synuclein would diffuse slower than a 
‘normal’ protein, (ii), diffusion would be through a medium that is more ‘crowded’ that simple cytosol.  Also our simplifying  
assumption is of one long axonal connection between ENS and brain stem, thus making no allowance for protein transport from 
one neuron to another [Desplats, 2009].  
 
The physiological concentration of α-synuclein varies on the location within a neuron, but is on average 100 µM [Raichur, 
2006], and under healthy conditions approximately 1% of the protein is misfolded [Sneppen, 2009]. The concentration of α-
synuclein misfolds in Parkinsonian brains has been calculated [Chiba-Falek, 2006] as four times greater than in healthy brains, so 
that on average the concentration of mis-folded α-synuclein in a Parkinsonian state could be expected to be approximately 4 µM. 
However, this does not account for variations throughout a neuron and other factors remarked upon by [Chiba-Falek, 2006]. 
Therefore, to be conservative in our calculations, we assumed that an external pathogen has created a much greater initial α-
synuclein misfold concentration of 17 µM at the trigger point in the ENS. 
 
Calculation of the diffusion times with these parameters indicate that it would take over 300 years for the concentration of 
protein at the end point in the lower brain stem to exceed 10 µM by diffusion alone. Computing the progression by diffusion over 
a 65 year period (the approximate age at which risk of Parkinson’s begins to become significant) the concentration of protein at 
the one metre end point is insignificantly small (less than 0.001 µM).    
 
 
SM3 Further reading 
Brundin P, Li JY, Holton JL, Lindvall O, Revesz T, (2008),  Research in motion: The enigma of Parkinson's disease pathology 
spread. Nat Rev Neurosci 9:741–745 
 Desplats, P, (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein PNAS 
vol. 106 no. 31, 13010–13015, doi: 10.1073/pnas.0903691106  
Lotharius, J. Brundin, P. (2002), Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein Nature Reviews 
Neuroscience 3, 932-942 (December 2002) | doi:10.1038/nrn983 
Kühn T, Ihalainen TO, Hyväluoma J, Dross N, Willman SF, et al. (2011) Protein 
Diffusion in Mammalian Cell Cytoplasm. PLoS ONE 6(8): e22962. doi:10.1371/journal.pone.0022962 
Chiba-Falek, O, Lopex, GJ, Nussbaum, RL, (2006) Levels of alpha-synclein mRNA in sporadic Parkinson disease patients, 
Movement Disorder, Oct 21 (10): 1703-8, http://www.ncbi.nlm.nih.gov/pubmed/16795004 
 
 
